Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-02-25 @ 1:54 AM
Study NCT ID:
NCT00963534
Status:
COMPLETED
Last Update Posted:
2018-03-12
First Post:
2009-08-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Sponsor:
Lund University Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
NLG-MCL4
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None